

January 26, 2024

**Mitsubishi Tanabe Pharma contribute funding to
Global Health Innovative Technology Fund's third phase
—Targeting treatments for infectious diseases that burden the developing world—**

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, "MTPC"), a member of the Mitsubishi Chemical Group, has endorsed the objectives of the Global Health Innovative Technology Fund (GHIT Fund) and has decided to provide 100 million yen from FY2023 through FY2027.

The GHIT Fund is a public-private partnership, originating in Japan in 2013, that advances the discovery of new drugs for infectious diseases that burden the developing world, such as malaria, tuberculosis, and neglected tropical diseases (NTDs). The GHIT Fund aims to bolster Japan's international contribution to global health through new drug R&D capabilities that leverage the advanced scientific and technical knowledge of Japanese pharmaceutical companies and other institutions.

MTPC has already contributed a total of 140 million yen for the first and second phases of the GHIT Fund. In addition, by utilizing grants from the GHIT Fund and its partnerships, two joint research are undergoing. One is a late-lead program for Malaria with MMV and the other is a hit-to-lead program for Chagas disease with DNDi.

MTPC has identified "Access to healthcare" as one of the important material issues that it needs to address. In addition to creating pharmaceuticals that address unmet medical needs, we will contribute to improving access to treatment of infectious diseases in developing countries through our participation in the GHIT Fund. In this way, we will provide hopeful options for all people facing illness.

Contact:
Mitsubishi Chemical Group Corporation
Corporate Communications Division
Osaka Corporate Communications Department
+81-6-6205-5119

<Reference>

■ The Global Health Innovative Technology Fund (GHIT Fund)

The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world's vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.

<https://www.ghitfund.org/en>